Spots Global Cancer Trial Database for Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid Tumors

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid Tumors

Official Title: Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid Tumors

Study ID: NCT02843204

Conditions

Malignant Solid Tumour

Interventions

Pembrolizumab

NK immunotherapy

Study Description

Brief Summary: The aim of this study is the safety and efficacy of anti-PD-1 plus NK immunotherapy to multiple solid tumors.

Detailed Description: By enrolling patients with solid tumors adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of the combined therapy using anti-PD-1 and natural killer (NK) cells. The safety will be evaluated by statistics of adverse reactions. The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS).